F1000Research (Mar 2021)

The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya [version 2; peer review: 2 approved]

  • Tri Pudy Asmarawati,
  • Alfian Nur Rosyid,
  • Satriyo Dwi Suryantoro,
  • Bagus Aulia Mahdi,
  • Choirina Windradi,
  • Prastuti Asta Wulaningrum,
  • Muhammad Vitanata Arifianto,
  • Bramantono Bramantono,
  • Erwin Astha Triyono,
  • Musofa Rusli,
  • Brian Eka Rachman,
  • Erika Marfiani,
  • Pepy Dwi Endraswari,
  • Usman Hadi,
  • Kuntaman Kuntaman,
  • Nasronudin Nasronudin

DOI
https://doi.org/10.12688/f1000research.31645.2
Journal volume & issue
Vol. 10

Abstract

Read online

Background: Data on the prevalence of bacterial co-infections among COVID-19 patients are limited, especially in our country, Indonesia. We aimed to assess the rate of bacterial co-infections in hospitalized COVID-19 patients and report the most common microorganisms involved and the antibiotic use in these patients. Methods: This study is a retrospective cohort study, among COVID-19 adult patients admitted to Universitas Airlangga Hospital Surabaya from 14 March-30 September 2020. The bacterial infection is defined based on clinical assessment, laboratory parameters, and microbiology results. Results: A total of 218 patients with moderate to critical illness and confirmed COVID-19 were included in this study. Bacterial infection was confirmed in 43 patients (19.7%). COVID-19 patients with bacterial infections had longer hospital length of stay (17.6 ± 6.62 vs 13.31±7.12), a higher proportion of respiratory failure, intensive care treatment, and ventilator use. COVID-19 patients with bacterial infection had a worse prognosis than those without bacterial infection (p<0.04). The empirical antibiotic was given to 75.2% of the patients. Gram-negative bacteria were commonly found as causative agents in this study (n = 39; 70.37%). Conclusion: COVID-19 patients with bacterial infection have a longer length of stay and worse outcomes. Healthcare-associated infections during intensive care treatment for COVID-19 patients must be carefully prevented.